Literature DB >> 16221381

The merits of vascular targeting for gynecologic malignancies.

Aparna A Kamat1, Anil K Sood.   

Abstract

Neovascularization is an early and critical step in tumor development and progression. Tumor vessels are distinct from their normal counterparts morphologically as well as at a molecular level. Recent studies on factors involved in tumor vascular development have identified new therapeutic targets for inhibiting tumor neovascularization and thus tumor progression. However, the process of tumor blood vessel formation is complex, and each tumor exhibits unique features in its vasculature. An understanding of the relative contribution of various pathways in the development of tumor vasculature is critical for developing effective and selective therapeutic approaches. Several such agents are currently in clinical trials, and many others are under development. In this review, the mechanisms and factors involved in tumor blood vessel formation are discussed. In addition, selected novel classes of antivascular therapies, including those targeting tumor endothelial cells and other components of the tumor vasculature, are summarized.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16221381      PMCID: PMC3139990          DOI: 10.1007/s11912-005-0009-x

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  59 in total

1.  Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice.

Authors:  D Hanahan; G Bergers; E Bergsland
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

2.  Circulating endothelial precursors: mystery, reality, and promise.

Authors:  S Rafii
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

3.  Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer.

Authors:  Limin Hu; Judith Hofmann; Charles Zaloudek; Napoleone Ferrara; Thomas Hamilton; Robert B Jaffe
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

4.  Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms.

Authors:  R M Shaheen; W W Tseng; D W Davis; W Liu; N Reinmuth; R Vellagas; A A Wieczorek; Y Ogura; D J McConkey; K E Drazan; C D Bucana; G McMahon; L M Ellis
Journal:  Cancer Res       Date:  2001-02-15       Impact factor: 12.701

5.  Pericyte loss and microaneurysm formation in PDGF-B-deficient mice.

Authors:  P Lindahl; B R Johansson; P Levéen; C Betsholtz
Journal:  Science       Date:  1997-07-11       Impact factor: 47.728

Review 6.  New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF.

Authors:  J Holash; S J Wiegand; G D Yancopoulos
Journal:  Oncogene       Date:  1999-09-20       Impact factor: 9.867

7.  Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants.

Authors:  H Gille; J Kowalski; B Li; J LeCouter; B Moffat; T F Zioncheck; N Pelletier; N Ferrara
Journal:  J Biol Chem       Date:  2000-10-31       Impact factor: 5.157

8.  Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer.

Authors:  Maurie Markman; James Hall; Daniel Spitz; Sheldon Weiner; Linda Carson; Linda Van Le; Mark Baker
Journal:  J Clin Oncol       Date:  2002-05-01       Impact factor: 44.544

9.  Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer.

Authors:  Brian C Cooper; Justine M Ritchie; Carrie L W Broghammer; Jeremy Coffin; Joel I Sorosky; Richard E Buller; Mary J C Hendrix; Anil K Sood
Journal:  Clin Cancer Res       Date:  2002-10       Impact factor: 12.531

10.  Tumor induction of VEGF promoter activity in stromal cells.

Authors:  D Fukumura; R Xavier; T Sugiura; Y Chen; E C Park; N Lu; M Selig; G Nielsen; T Taksir; R K Jain; B Seed
Journal:  Cell       Date:  1998-09-18       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.